Vivus Sells Erectile Treatment for $23.5M

Vivus (NASDAQ: VVUS), the Mountain View, CA-based developer of an obesity drug, said today it has sold its marketed treatment for erectile dysfunction. Lakewood, NJ-based Meda agreed to pay $23.5 million for the assets related to transurethral alprostadil (Muse). Meda has been business partners with Vivus in Europe since 2000, Vivus said. Selling the Muse assets will allow Vivus to focus on commercializing the obesity drug (Qnexa) that it is seeking to market in the U.S.

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

One response to “Vivus Sells Erectile Treatment for $23.5M”

  1. This is probably a good idea on VVUS’s part, they have qnexa and avanafil products and it is probably better if they don’t spread themselves out too thin.